EmeraMed Limited Company completed the clinical portion of its Phase 2a pilot trial for Irminix (the new name of OSR1 product). The trial was reported on 36 mercury intoxicated gold miners in Ecuador, in January 2016. This pilot study was designed to gather data in preparation for the pivotal Phase 2/3 trial expected in early 2017.
The findings were:
- 52% decrease in mental and physical fatigue induced by mercury toxicity
- Decrease in Blood and Urine Mercury levels in the highest dose group
- No significant adverse events were reported, although there were 4 times more significant adverse events in the placebo group.
The next step in the regulatory process is to perform the pivotal Phase 2/3 trial in 2017.
Please visit the Company website, www.EmeraMed.com, for updates as they become available. Thank you for your interest in EmeraMed and its flagship drug product, Irminix.
With kind regards, Boyd E. Haley
Print